Vitamin D status was not associated with 'one-year' progression of coronary artery disease, assessed by coronary angiography in statin-treated patients

Eirik Degerud; Kjetil H Løland; Ottar Nygård; Øivind Midttun; Per M Ueland; Reinhard Seifert; Elin Strand; Øivind Bleie; Jutta Dierkes

doi:10.1177/2047487314522137

Vitamin D status was not associated with 'one-year' progression of coronary artery disease, assessed by coronary angiography in statin-treated patients

Eur J Prev Cardiol. 2015 May;22(5):594-602. doi: 10.1177/2047487314522137. Epub 2014 Jan 30.

Authors

Eirik Degerud¹, Kjetil H Løland², Ottar Nygård³, Øivind Midttun⁴, Per M Ueland⁵, Reinhard Seifert⁶, Elin Strand², Øivind Bleie⁶, Jutta Dierkes⁷

Affiliations

¹ Department of Clinical Medicine, University of Bergen, Norway eirik.degerud@k1.uib.no.
² Department of Clinical Science, University of Bergen, Norway.
³ Department of Clinical Science, University of Bergen, Norway Department of Heart Disease, Haukeland University Hospital, Norway.
⁴ Bevital AS, Norway.
⁵ Department of Clinical Science, University of Bergen, Norway Laboratory of Clinical Biochemistry, Haukeland University Hospital, Norway.
⁶ Department of Heart Disease, Haukeland University Hospital, Norway.
⁷ Department of Clinical Medicine, University of Bergen, Norway.

PMID: 24480878
DOI: 10.1177/2047487314522137

Abstract

Background: Low vitamin D status is associated with increased risk of cardiovascular disease and may be involved in atherosclerosis. Our aim was to assess the association between vitamin D status and the progression of coronary artery disease (CAD).

Methods and results: We measured 25-hydroxyvitamin D3 (25OHD3) by liquid chromatography tandem mass spectrometry (LC-MS/MS) in plasma from 348 participants with established CAD (84% males, mean ± standard deviation (SD) age 60 ± 10 years) of the Western Norway B-vitamin Intervention Trial (WENBIT, 1999-2006). The patients underwent invasive coronary angiography (CA) and percutaneous coronary intervention at baseline and a second CA after 302 ± 79 days of follow-up. From the angiograms, minimal lumen diameter (MLD) and diameter stenosis (DS) of atherosclerotic lesions were obtained. Significant CAD in non-intervened vessels was found in 309 coronary arteries from 183 participants either at baseline and/or at follow-up. To assess the association between levels of 25OHD3 and CAD progression in non-intervened vessels, we applied a linear quantile fitted mixed effects model with MLD or DS measured at follow-up as a function of continuous 25OHD3 concentrations. There were no statistically significant associations between plasma 25OHD3 concentrations (median: 63.9, 95% confidence interval (CI): 48.1-78.5 nmol/l) measured at baseline and the follow-up measures of either MLD (estimated effect per 10 nmol/l increase of 25OHD3 and 95% CI: -0.015 (-0.032-0.002) mm, p = 0.088) or DS (0.225 (-0.354-0.804) percentage points, p = 0.444). Multivariate adjustment did not alter these results.

Conclusion: Plasma 25OHD3 levels were not associated with 'one-year' progression of CAD, assessed by CA in statin-treated patients.

Keywords: 25-hydroxyvitamin D; Vitamin D; atherosclerosis; calcifediol; coronary angiography; coronary artery disease; disease progression.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Calcifediol / blood*
Chromatography, Liquid
Coronary Angiography / methods*
Coronary Artery Disease / blood*
Coronary Artery Disease / diagnosis*
Coronary Artery Disease / drug therapy
Disease Progression
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Male
Middle Aged
Tandem Mass Spectrometry
Vitamins / blood*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Vitamins
Calcifediol